CHICAGO, Jun 04, 2007 (BUSINESS WIRE) -- Cytogen Corporation (NASDAQ: CYTO) today reported results from clinical trials demonstrating that QUADRAMET (samarium Sm-153 lexidronam injection) can be safely administered to prostate cancer patients who are also receiving the chemotherapy docetaxel (Taxotere(R), Sanofi-Aventis). Clinical data also support further evaluation of the combination regimen for the treatment of prostate cancer in a Phase 2 program. The results were presented and/or published at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Chicago, Illinois and are summarized herein.
